Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma

  1. Simone Hettmer
  2. Anna C Schinzel
  3. Daria Tchessalova
  4. Michaela Schneider
  5. Christina L. Parker
  6. Roderick Bronson
  7. Nigel G.J. Richards
  8. William Hahn
  9. Amy J Wagers  Is a corresponding author
  1. University Medical Center Freiburg, Germany
  2. Dana-Farber Cancer Institute, United States
  3. University of Michigan, United States
  4. University of North Carolina, United States
  5. Harvard University, United States
  6. Indiana University - Purdue University Indianapolis, United States
  7. Dana Farber Cancer Institute, United States

Abstract

Current therapies for sarcomas are often inadequate. This study sought to identify actionable gene targets by selective targeting of the molecular networks that support sarcoma cell proliferation. Silencing of asparagine synthetase (ASNS), an amidotransferase that converts aspartate into asparagine, produced the strongest inhibitory effect on sarcoma growth in a functional genomic screen of mouse sarcomas generated by oncogenic Kras and Cdkn2a. ASNS silencing in mouse and human sarcoma cell lines reduced the percentage of S phase cells and impeded new polypeptide synthesis. These effects of ASNS silencing were reversed by exogenous supplementation with asparagine. Also, asparagine depletion via the ASNS inhibitor amino sulfoximine 5 (AS5) or asparaginase inhibited mouse and human sarcoma growth in vitro, and genetic silencing of ASNS in mouse sarcoma cells combined with depletion of plasma asparagine inhibited tumor growth in vivo. Asparagine reliance of sarcoma cells may represent a metabolic vulnerability with potential anti-sarcoma therapeutic value.

Article and author information

Author details

  1. Simone Hettmer

    Pediatric Hematology/ Oncology, University Medical Center Freiburg, Freiburg, Germany
    Competing interests
    No competing interests declared.
  2. Anna C Schinzel

    Medical Oncology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
  3. Daria Tchessalova

    Neuroscience Graduate Program, University of Michigan, Ann Arbor, United States
    Competing interests
    No competing interests declared.
  4. Michaela Schneider

    Pediatric hematology/ oncology, University Medical Center Freiburg, Freiburg, Germany
    Competing interests
    No competing interests declared.
  5. Christina L. Parker

    Molecular Pharmaceutics, University of North Carolina, Chapel Hill, United States
    Competing interests
    No competing interests declared.
  6. Roderick Bronson

    Harvard Medical School, Harvard University, Boston, United States
    Competing interests
    No competing interests declared.
  7. Nigel G.J. Richards

    Chemistry & Chemical Biology, Indiana University - Purdue University Indianapolis, Indianapolis, United States
    Competing interests
    No competing interests declared.
  8. William Hahn

    Dana Farber Cancer Institute, *, United States
    Competing interests
    No competing interests declared.
  9. Amy J Wagers

    Harvard Stem Cell Institute, Harvard University, United States
    For correspondence
    amy.wagers@joslin.harvard.edu
    Competing interests
    Amy J Wagers, Reviewing editor, eLife.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the Joslin Diabetes Center. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Joslin Diabetes Center. All surgery was performed under tribromoethanol or isoflurane anesthesia, and every effort was made to minimize suffering.

Copyright

© 2015, Hettmer et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,707
    views
  • 634
    downloads
  • 52
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Simone Hettmer
  2. Anna C Schinzel
  3. Daria Tchessalova
  4. Michaela Schneider
  5. Christina L. Parker
  6. Roderick Bronson
  7. Nigel G.J. Richards
  8. William Hahn
  9. Amy J Wagers
(2015)
Functional genomic screening reveals asparagine dependence as a metabolic vulnerability in sarcoma
eLife 4:e09436.
https://doi.org/10.7554/eLife.09436

Share this article

https://doi.org/10.7554/eLife.09436

Further reading

    1. Cancer Biology
    2. Cell Biology
    Ida Marie Boisen, Nadia Krarup Knudsen ... Martin Blomberg Jensen
    Research Article

    Testicular microcalcifications consist of hydroxyapatite and have been associated with an increased risk of testicular germ cell tumors (TGCTs) but are also found in benign cases such as loss-of-function variants in the phosphate transporter SLC34A2. Here, we show that fibroblast growth factor 23 (FGF23), a regulator of phosphate homeostasis, is expressed in testicular germ cell neoplasia in situ (GCNIS), embryonal carcinoma (EC), and human embryonic stem cells. FGF23 is not glycosylated in TGCTs and therefore cleaved into a C-terminal fragment which competitively antagonizes full-length FGF23. Here, Fgf23 knockout mice presented with marked calcifications in the epididymis, spermatogenic arrest, and focally germ cells expressing the osteoblast marker Osteocalcin (gene name: Bglap, protein name). Moreover, the frequent testicular microcalcifications in mice with no functional androgen receptor and lack of circulating gonadotropins are associated with lower Slc34a2 and higher Bglap/Slc34a1 (protein name: NPT2a) expression compared with wild-type mice. In accordance, human testicular specimens with microcalcifications also have lower SLC34A2 and a subpopulation of germ cells express phosphate transporter NPT2a, Osteocalcin, and RUNX2 highlighting aberrant local phosphate handling and expression of bone-specific proteins. Mineral disturbance in vitro using calcium or phosphate treatment induced deposition of calcium phosphate in a spermatogonial cell line and this effect was fully rescued by the mineralization inhibitor pyrophosphate. In conclusion, testicular microcalcifications arise secondary to local alterations in mineral homeostasis, which in combination with impaired Sertoli cell function and reduced levels of mineralization inhibitors due to high alkaline phosphatase activity in GCNIS and TGCTs facilitate osteogenic-like differentiation of testicular cells and deposition of hydroxyapatite.

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.